Premium
Ultrarapid iron polymaltose infusion for iron deficiency anaemia: a pilot safety study
Author(s) -
Banakh Iouri,
Turek Martha,
Chin Jong,
Churchill Travis
Publication year - 2020
Publication title -
journal of pharmacy practice and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.222
H-Index - 22
eISSN - 2055-2335
pISSN - 1445-937X
DOI - 10.1002/jppr.1582
Subject(s) - medicine , adverse effect , iron deficiency , prospective cohort study , intravenous iron , open label , anesthesia , pediatrics , surgery , anemia
Abstract Treatment of iron deficiency is often achieved via single administration of intravenous iron polymaltose (IP) as a prolonged infusion or multiple infusions of more rapidly administered products. This study examined the safety of IP for total body iron replacement administered as ultrarapid infusions. A prospective open‐label cohort pilot study was conducted at a tertiary centre to investigate IP infusions with doses up to 500–1500 mg administered over 30 or 15 min (10 patients in each group). Adverse effects were graded as mild, moderate or severe, with monitoring during the infusion and a 1‐week follow‐up period. Three patients in each group experienced four mild adverse effects during the infusion. During the follow‐up period, two participants in each group experienced adverse effects, with one in each group experiencing a moderate adverse effect requiring treatment with paracetamol. In this pilot study, the safety outcomes of ultrarapid infusions were similar to both 4‐ and 1‐h infusions of iron polymaltose and to ferric carboxymaltose. Fully powered studies of ultrarapid iron polymaltose are warranted given the safety results of this study.